Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P53672
UPID:
CRBA2_HUMAN
Alternative names:
Beta-A2 crystallin
Alternative UPACC:
P53672; Q4ZFX0; Q9Y562
Background:
Beta-crystallin A2, also known as Beta-A2 crystallin, plays a pivotal role in the vertebrate eye lens, serving as a dominant structural component. This protein's unique structure and function are crucial for maintaining lens transparency and refractive properties, essential for clear vision.
Therapeutic significance:
Cataract 42, a condition characterized by lens opacification leading to visual impairment or blindness, is directly linked to variants affecting the Beta-crystallin A2 gene. Understanding the role of Beta-crystallin A2 could open doors to potential therapeutic strategies for this and related ocular diseases.